Abstract
Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.
| Original language | English |
|---|---|
| Article number | 830 |
| Journal | Pharmacy Practice |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Oct 2016 |
Fingerprint
Keywords
- Anti-retroviral agents
- Antiretroviral therapy
- Benzoxazines
- CD4 lymphocyte count
- Drug combinations
- Emtricitabine
- Highly active
- Malaysia
- Tenofovir
- Viral load
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Simplification of HAART therapy on ambulatory HIV patients in Malaysia : A randomized controlled trial. / Velvanathan, Tineshwaran; Islahudin, Farida Hanim; Sim, Benedict L H; Taha, Nur Akmar.
In: Pharmacy Practice, Vol. 14, No. 4, 830, 01.10.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Simplification of HAART therapy on ambulatory HIV patients in Malaysia
T2 - A randomized controlled trial
AU - Velvanathan, Tineshwaran
AU - Islahudin, Farida Hanim
AU - Sim, Benedict L H
AU - Taha, Nur Akmar
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.
AB - Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.
KW - Anti-retroviral agents
KW - Antiretroviral therapy
KW - Benzoxazines
KW - CD4 lymphocyte count
KW - Drug combinations
KW - Emtricitabine
KW - Highly active
KW - Malaysia
KW - Tenofovir
KW - Viral load
UR - http://www.scopus.com/inward/record.url?scp=85006961521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006961521&partnerID=8YFLogxK
U2 - 10.18549/PharmPract.2016.04.830
DO - 10.18549/PharmPract.2016.04.830
M3 - Article
AN - SCOPUS:85006961521
VL - 14
JO - Pharmacy Practice
JF - Pharmacy Practice
SN - 1885-642X
IS - 4
M1 - 830
ER -